COMPANY

Juvena Therapeutics Inc.

HQ: Redwood City, CA source · juvenatherapeutics.com ↗ · West Coast

Keywords: protein therapeutics myotonic dystrophy musculoskeletal metabolic metabolic diseases JUV-161

Location: Redwood City, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Feb 28, 2026 Trial start Phase 1/Phase 2: To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI) source ↗
Jan 12, 2026 Raise Private equity round — Series B: $33.5M (total, as published), announced Jan 12, 2026. Source: company release on GlobeNewswire. source ↗
Jun 11, 2025 Partnership Partnership / licensing announced Jun 11, 2025. Source: company release on GlobeNewswire. source ↗
May 14, 2025 Trial start Phase 1: First-In-Human Study to Evaluate Single and Multiple Ascending Doses of JUV-161 in Healthy Adult Volunteers source ↗

Raised: $33.5M. Last 2 years.

Jan 12, 2026 Private equity round — Series B: $33.5M (total, as published), announced Jan 12, 2026. Source: company release on GlobeNewswire. source ↗
Jun 11, 2025 Partnership / licensing announced Jun 11, 2025. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06918925	First-In-Human Study to Evaluate Single and Multiple Ascending Doses of JUV-161 in Healthy Adult Volunteers	Phase 1	Active, not recruiting	May 14, 2025	May 30, 2026 (actual)
NCT07397468	To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)	Phase 1/Phase 2	Recruiting	Feb 28, 2026	Jul 31, 2026 (estimated)